bluuebunny/crossref_metadata_2025 huggingface dataset:
Supplemental Table 1 from New DNA Methylation Markers for Pancreatic Cancer: Discovery, Tissue Validation, and Pilot Testing in Pancreatic Juice
Authors: Kisiel John B. , Raimondo Massimo , Taylor William R. , Yab Tracy C. , Mahoney Douglas W. , Sun Zhifu , Middha Sumit , Baheti Saurabh , Zou Hongzhi , Smyrk Thomas C. , Boardman Lisa A. , Petersen Gloria M. , Ahlquist David A.
Published: April 2023

Supplemental Table 1. AUC and 95% confidence intervals for the technical validation study
Supplementary Table 2 from Subclonal Genomic Architectures of Primary and Metastatic Colorectal Cancer Based on Intratumoral Genetic Heterogeneity
Authors: Kim Tae-Min , Jung Seung-Hyun , An Chang Hyeok , Lee Sung Hak , Baek In-Pyo , Kim Min Sung , Park Sung-Won , Rhee Je-Keun , Lee Sug-Hyung , Chung Yeun-Jun
Published: April 2023

Supplementary Table 2. The mutations observed at least once for the regional biopsies across five CRC genomes. Genomic coordinates are according to hg19. The sequencechanges (Ref and Alt as reference and mutant sequences, respectively) are shown with the corresponding functional categories as reported by ANNOVAR. The ANNOVARreports are shown in the separate column (Annovar description). The color schemes for SC (spatial categories) are as shown in Main Figure 1. The mutations in the biopsies of primary (black; P) and metastatic lesions (purple; M) are shown in the matrix.
Supplemental Methods from New DNA Methylation Markers for Pancreatic Cancer: Discovery, Tissue Validation, and Pilot Testing in Pancreatic Juice
Authors: Kisiel John B. , Raimondo Massimo , Taylor William R. , Yab Tracy C. , Mahoney Douglas W. , Sun Zhifu , Middha Sumit , Baheti Saurabh , Zou Hongzhi , Smyrk Thomas C. , Boardman Lisa A. , Petersen Gloria M. , Ahlquist David A.
Published: April 2023

Supplemental Methods. Supplemental methods of DNA extraction and quantitative methylation specific polymerase chain reaction
Supplemental Figures 1-6 from New DNA Methylation Markers for Pancreatic Cancer: Discovery, Tissue Validation, and Pilot Testing in Pancreatic Juice
Authors: Kisiel John B. , Raimondo Massimo , Taylor William R. , Yab Tracy C. , Mahoney Douglas W. , Sun Zhifu , Middha Sumit , Baheti Saurabh , Zou Hongzhi , Smyrk Thomas C. , Boardman Lisa A. , Petersen Gloria M. , Ahlquist David A.
Published: April 2023

Supplemental Figures 1-6. Supplemental Figure 1. A typical KRAS Sanger dye termination sequencing trace for a pancreatic cancer sample. The arrow indicates the mutation site; the black peak represents a wild-type allele and the red peak represents the mutant allele. Supplemental Figure 2. (A) Copy numbers per sample of methylated KCNK12 assayed form pancreatic juice of patients with normal pancreas (NP), chronic pancreatitis (CP), high grade dysplastic main-duct intraductal pancreatic mucinous neoplasm (IPMN), and pancreatic cancer (PC) were used to calculate (B) receiver operating characteristics curves of methylated KCNK12 for the detection of PC in comparison to NP (black) and CP (grey). Supplemental Figure 3. (A) Copy numbers per sample of methylated CLEC11A assayed form pancreatic juice of patients with normal pancreas (NP), chronic pancreatitis (CP), high grade dysplastic main-duct intraductal pancreatic mucinous neoplasm (IPMN), and pancreatic cancer (PC) were used to calculate (B) receiver operating characteristics curves of methylated CLEC11A for the detection of PC in comparison to NP (black) and CP (grey). Supplemental Figure 4. (A) Copy numbers per sample of methylated NDRG4 assayed form pancreatic juice of patients with normal pancreas (NP), chronic pancreatitis (CP), high grade dysplastic main-duct intraductal pancreatic mucinous neoplasm (IPMN), and pancreatic cancer (PC) were used to calculate (B) receiver operating characteristics curves of methylated NDRG4 for the detection of PC in comparison to NP (black) and CP (grey). Supplemental Figure 5. (A) Genomic copy numbers of methylated IKZF1 in normal pancreas (NP), chronic pancreatitis (CP), high grade dysplastic main-duct intraductal pancreatic mucinous neoplasm (IPMN), and pancreatic cancer (PC) were used to calculate (B) receiver operating characteristics curves of methylated IKZF1 for the detection of PC in comparison to NP (black) and CP (grey). Supplemental Figure 6. (A) Genomic copy numbers of methylated PKRCB in normal pancreas (NP), chronic pancreatitis (CP), high grade dysplastic main-duct intraductal pancreatic mucinous neoplasm (IPMN), and pancreatic cancer (PC) were used to calculate (B) receiver operating characteristics curves of methylated PKRCB for the detection of PC in comparison to NP (black) and CP (grey).
Supplementary Fig. S4 from Subclonal Genomic Architectures of Primary and Metastatic Colorectal Cancer Based on Intratumoral Genetic Heterogeneity
Authors: Kim Tae-Min , Jung Seung-Hyun , An Chang Hyeok , Lee Sung Hak , Baek In-Pyo , Kim Min Sung , Park Sung-Won , Rhee Je-Keun , Lee Sug-Hyung , Chung Yeun-Jun
Published: April 2023

Supplementary Fig. S4. Immunohistochemical identification of decreased PCDH9 expression in liver metastasis of a colon cancer. A colon cancer with ITH of PCDH9 deletion identified by both aCGH and qPCR shows positive PCDH9 immunostaining in normal colonic glands (A) and a primary colon tissue (B), but decreased PCDH9 immunostaining in two metastatic sites (C and D) in the liver (frozen tissues).
Supplementary Fig. S1 from Subclonal Genomic Architectures of Primary and Metastatic Colorectal Cancer Based on Intratumoral Genetic Heterogeneity
Authors: Kim Tae-Min , Jung Seung-Hyun , An Chang Hyeok , Lee Sung Hak , Baek In-Pyo , Kim Min Sung , Park Sung-Won , Rhee Je-Keun , Lee Sug-Hyung , Chung Yeun-Jun
Published: April 2023

Supplementary Fig. S1. Schematic protocol of tissue collection in five colon cancers with liver metastasis. In each colon cancer patient, 2 to 5 tumor fragments each apart at least from 0.5 cm were collected from colon. In parallel, 2 to 6 separate metastatic nodules in the liver were collected from each patient.
Supplementary Table S3 from PLEKHA5 as a Biomarker and Potential Mediator of Melanoma Brain Metastasis
Authors: Jilaveanu Lucia B. , Parisi Fabio , Barr Meaghan L. , Zito Christopher R. , Cruz-Munoz William , Kerbel Robert S. , Rimm David L. , Bosenberg Marcus W. , Halaban Ruth , Kluger Yuval , Kluger Harriet M.
Published: April 2023

Supplementary Table S3: This table provides the results of a multivariable Cox proportional hazards analysis of PLEKHA5 and other clinical variables. PLEKHA5 was independently associated with development of early brain metastases.
Supplemental Figure 6 from Chaperonin Containing TCP-1 Protein Level in Breast Cancer Cells Predicts Therapeutic Application of a Cytotoxic Peptide
Authors: Bassiouni Rania , Nemec Kathleen N. , Iketani Ashley , Flores Orielyz , Showalter Anne , Khaled Amr S. , Vishnubhotla Priya , Sprung Robert W. , Kaittanis Charalambos , Perez Jesus M. , Khaled Annette R.
Published: April 2023

Supplemental figure with genomic data and results from tissue microarrays
Supplemental Figure 5 from Chaperonin Containing TCP-1 Protein Level in Breast Cancer Cells Predicts Therapeutic Application of a Cytotoxic Peptide
Authors: Bassiouni Rania , Nemec Kathleen N. , Iketani Ashley , Flores Orielyz , Showalter Anne , Khaled Amr S. , Vishnubhotla Priya , Sprung Robert W. , Kaittanis Charalambos , Perez Jesus M. , Khaled Annette R.
Published: April 2023

Supplemental figure showing mouse tumor data
Supplemental Figure 2 from Chaperonin Containing TCP-1 Protein Level in Breast Cancer Cells Predicts Therapeutic Application of a Cytotoxic Peptide
Authors: Bassiouni Rania , Nemec Kathleen N. , Iketani Ashley , Flores Orielyz , Showalter Anne , Khaled Amr S. , Vishnubhotla Priya , Sprung Robert W. , Kaittanis Charalambos , Perez Jesus M. , Khaled Annette R.
Published: April 2023

Supplemental figure with nanoparticle uptake data and IC50 calculations
Supplementary Figure S1 from PLEKHA5 as a Biomarker and Potential Mediator of Melanoma Brain Metastasis
Authors: Jilaveanu Lucia B. , Parisi Fabio , Barr Meaghan L. , Zito Christopher R. , Cruz-Munoz William , Kerbel Robert S. , Rimm David L. , Bosenberg Marcus W. , Halaban Ruth , Kluger Yuval , Kluger Harriet M.
Published: April 2023

Kaplan-Meier curves for PLEKHA5 expression and development of other distant metastases. There was no correlation between expression and time to development of lung, liver or bone metastasis.
Supplemental Table 1 from Zinc Finger Nucleases Targeting the Human Papillomavirus E7 Oncogene Induce E7 Disruption and a Transformed Phenotype in HPV16/18-Positive Cervical Cancer Cells
Authors: Ding Wencheng , Hu Zheng , Zhu Da , Jiang Xiaohui , Yu Lan , Wang Xiaoli , Zhang Changlin , Wang Liming , Ji Teng , Li Kezhen , He Dan , Xia Xi , Liu Dan , Zhou Jianfeng , Ma Ding , Wang Hui
Published: April 2023

Target sequences and construction approaches of ZFNs used in this manuscript.
Supplemental Figure 1 from Zinc Finger Nucleases Targeting the Human Papillomavirus E7 Oncogene Induce E7 Disruption and a Transformed Phenotype in HPV16/18-Positive Cervical Cancer Cells
Authors: Ding Wencheng , Hu Zheng , Zhu Da , Jiang Xiaohui , Yu Lan , Wang Xiaoli , Zhang Changlin , Wang Liming , Ji Teng , Li Kezhen , He Dan , Xia Xi , Liu Dan , Zhou Jianfeng , Ma Ding , Wang Hui
Published: April 2023

IHC stainings of PCNA, Caspase-3 and CD31 in the non-necrosis area of xenografts.
Table S6 from SRC3 Phosphorylation at Serine 543 Is a Positive Independent Prognostic Factor in ER-Positive Breast Cancer
Authors: Zwart Wilbert , Flach Koen D. , Rudraraju Bharath , Abdel-Fatah Tarek M.A. , Gojis Ondrej , Canisius Sander , Moore David , Nevedomskaya Ekaterina , Opdam Mark , Droog Marjolein , Hofland Ingrid , Chan Steve , Shaw Jacqui , Ellis Ian O. , Coombes R. Charles , Carroll Jason S. , Ali Simak , Palmieri Carlo
Published: April 2023

Motif analyses for chromatin binding sites shared or selectively enriched for SRC3-pS543 and ERï�¡ in tumor #1.
Table S5 from SRC3 Phosphorylation at Serine 543 Is a Positive Independent Prognostic Factor in ER-Positive Breast Cancer
Authors: Zwart Wilbert , Flach Koen D. , Rudraraju Bharath , Abdel-Fatah Tarek M.A. , Gojis Ondrej , Canisius Sander , Moore David , Nevedomskaya Ekaterina , Opdam Mark , Droog Marjolein , Hofland Ingrid , Chan Steve , Shaw Jacqui , Ellis Ian O. , Coombes R. Charles , Carroll Jason S. , Ali Simak , Palmieri Carlo
Published: April 2023

GO pathway analysis of genes with a transcription start site <20kb from a unique or shared binding site of total SRC3 or pSRC3.
Figure S4. TC-1 tumor rechallenge and metastasis model. from Combination of Photodynamic Therapy and Specific Immunotherapy Efficiently Eradicates Established Tumors
Authors: Kleinovink Jan Willem , van Driel Pieter B. , Snoeks Thomas J. , Prokopi Natasa , Fransen Marieke F. , Cruz Luis J. , Mezzanotte Laura , Chan Alan , Löwik Clemens W. , Ossendorp Ferry
Published: April 2023

(A) Tumor outgrowth and survival curves after TC-1 tumor challenge in mice cured from their TC-1 tumor by combination therapy of PDT and peptide vaccination, compared to naïve control mice. Pooled data from 3 independent experiments, 13-18 mice per group. Survival curve statistics by LogRank Χ2 test, statistical significance *** = p<0.001. (B) The experimental setup of the TC-1 metastasis model is shown on a timescale starting with inoculation of the primary tumor at day 0. Mice were inoculated with TC-1 tumor cells in both flanks followed by systemic peptide vaccination and PDT of only the primary tumor.
Supplementary Table 1 from A Phase I First-in-Human Study of Nesvacumab (REGN910), a Fully Human Anti–Angiopoietin-2 (Ang2) Monoclonal Antibody, in Patients with Advanced Solid Tumors
Authors: Papadopoulos Kyriakos P. , Kelley Robin Kate , Tolcher Anthony W. , Razak Albiruni R. Abdul , Van Loon Katherine , Patnaik Amita , Bedard Philippe L. , Alfaro Ariceli A. , Beeram Muralidhar , Adriaens Lieve , Brownstein Carrie M. , Lowy Israel , Kostic Ana , Trail Pamela A. , Gao Bo , DiCioccio A. Thomas , Siu Lillian L.
Published: April 2023

Supplementary Table 1. Summary of the Most Common (>10%) Treatment-Emergent Adverse Events
Supplementary Figures 1-9 from A Phase I First-in-Human Study of Nesvacumab (REGN910), a Fully Human Anti–Angiopoietin-2 (Ang2) Monoclonal Antibody, in Patients with Advanced Solid Tumors
Authors: Papadopoulos Kyriakos P. , Kelley Robin Kate , Tolcher Anthony W. , Razak Albiruni R. Abdul , Van Loon Katherine , Patnaik Amita , Bedard Philippe L. , Alfaro Ariceli A. , Beeram Muralidhar , Adriaens Lieve , Brownstein Carrie M. , Lowy Israel , Kostic Ana , Trail Pamela A. , Gao Bo , DiCioccio A. Thomas , Siu Lillian L.
Published: April 2023

Supplementary Figure 1 Total Nesvacumab (REGN910) and Total Ang2 vs Time (cycle 1) following IV infusion in Patients. Supplementary Figure 2 Serum levels of ESM1, SDF-1, PLGF-1 and sVCAM-1 following Nesvacumab (REGN910) treatment. Supplementary Figure 3 Correlative analysis of baseline serum Ang2, ESM-1, SDF-1 ,PIGF and cVCAM-1 and treatment duration. Supplementary Figure 4 Correlative analysis of baseline Ang2 in tumor vessels and treatment duration/response. Supplementary Figure 5 Ang2 and VEGF-A protein levels in tumor tissue pre and post treatment with Nesvacumab (REGN910). Supplementary Figure 6 Biomarker analysis of archival tumor tissue. Supplementary Figure 7 Microvascular density in tumor tissue pre and post treatment with Nesvacumab (REGN910). Supplementary Figure 8 Tumor cell proliferation in tumor tissue pre and post treatment with Nesvacumab (REGN910). Supplementary Figure 9 TIE-2 protein levels associated with tumor vessels pre and post treatment with Nesvacumab (REGN910)
Supplementary Figure 2 from Identification of Biological Relevant Minor Histocompatibility Antigens within the B-lymphocyte–Derived HLA-Ligandome Using a Reverse Immunology Approach
Authors: Hombrink Pleun , Hassan Chopie , Kester Michel G.D. , Jahn Lorenz , Pont Margot J. , de Ru Arnoud H. , van Bergen Cornelis A.M. , Griffioen Marieke , Falkenburg J.H. Frederik , van Veelen Peter A. , Heemskerk Mirjam H.M.
Published: April 2023

Supplementary Figure 2. Gene expression profiles of CLYBL (A) and TEP1 (B) were analyzed.
Supplementary Figure 1 from Identification of Biological Relevant Minor Histocompatibility Antigens within the B-lymphocyte–Derived HLA-Ligandome Using a Reverse Immunology Approach
Authors: Hombrink Pleun , Hassan Chopie , Kester Michel G.D. , Jahn Lorenz , Pont Margot J. , de Ru Arnoud H. , van Bergen Cornelis A.M. , Griffioen Marieke , Falkenburg J.H. Frederik , van Veelen Peter A. , Heemskerk Mirjam H.M.
Published: April 2023

Supplementary Figure 1. The HLA-binding affinity of 25 eluted highly potential MiHA candidates was analyzed by a binding assay that is based on HLA-recovery after UV-exchange monomer technology.
Supplementary Figures 1 - 3 from Alterations Associated with Androgen Receptor Gene Activation in Salivary Duct Carcinoma of Both Sexes: Potential Therapeutic Ramifications
Authors: Mitani Yoshitsugu , Rao Pulivarthi H. , Maity Sankar N. , Lee Yu-Chen , Ferrarotto Renata , Post Julian C. , Licitra Lisa , Lippman Scott M. , Kies Merrill S. , Weber Randal S. , Caulin Carlos , Lin Sue-Hwa , El-Naggar Adel K.
Published: April 2023

Supplementary Figure S1. Distribution of RET981 cell line. Supplementary Figure S2. Detection of AR splice variants in SDCs. Supplementary Figure S3. Cleaved PARP increased by AR siRNAs.
Supplementary Figure 1 from Integrated Genomic Profiling, Therapy Response, and Survival in Adult Acute Myelogenous Leukemia
Authors: Parkin Brian , Ouillette Peter , Yildiz Mehmet , Saiya-Cork Kamlai , Shedden Kerby , Malek Sami N.
Published: April 2023

Supplementary Figure 1. Gene mutations/structural rearrangements, MADR, SNP-A lesion load and response to induction therapy.
Supplementary Figure 2 from Not all NOTCH Is Created Equal: The Oncogenic Role of NOTCH2 in Bladder Cancer and Its Implications for Targeted Therapy
Authors: Hayashi Tetsutaro , Gust Kilian M. , Wyatt Alexander W. , Goriki Akihiro , Jäger Wolfgang , Awrey Shannon , Li Na , Oo Htoo Zarni , Altamirano-Dimas Manuel , Buttyan Ralph , Fazli Ladan , Matsubara Akio , Black Peter C.
Published: April 2023

NOTCH2-induced cell invasion was blocked by downstream inhibition of canonical NOTCH2 signaling.
Supplementary Figure 1 from Not all NOTCH Is Created Equal: The Oncogenic Role of NOTCH2 in Bladder Cancer and Its Implications for Targeted Therapy
Authors: Hayashi Tetsutaro , Gust Kilian M. , Wyatt Alexander W. , Goriki Akihiro , Jäger Wolfgang , Awrey Shannon , Li Na , Oo Htoo Zarni , Altamirano-Dimas Manuel , Buttyan Ralph , Fazli Ladan , Matsubara Akio , Black Peter C.
Published: April 2023

NOTCH2 overexpression promoted bladder cancer progression through increased proliferation and invasion.
Supplementary Table S1 from Development of Engineered T Cells Expressing a Chimeric CD16-CD3ζ Receptor to Improve the Clinical Efficacy of Mogamulizumab Therapy Against Adult T-Cell Leukemia
Authors: Tanaka Hiroki , Fujiwara Hiroshi , Ochi Fumihiro , Tanimoto Kazushi , Casey Nicholas , Okamoto Sachiko , Mineno Junichi , Kuzushima Kiyotaka , Shiku Hiroshi , Sugiyama Takashi , Barrett A. John , Yasukawa Masaki
Published: April 2023

In our limited experience with Mog monotherapy for relapsed/refractory ATL (including the case shown in Fig.S3), excluding patients who received allo-HSCT and combined therapy with Mog and intensified chemotherapy mSLG15(ref.32) had shown that lymphocyte counts during Mog monotherapy in patients for whom the treatment failed to suppress disease progression (failure n=4) tended to be lower than that when Mog monotherapy successfully controlled disease (successful n=2). Total time points when cell counts were measured were shown, respectively. Data indicated as mean {plus minus} SD, respectively.
Supplementary Figure S2 from Development of Engineered T Cells Expressing a Chimeric CD16-CD3ζ Receptor to Improve the Clinical Efficacy of Mogamulizumab Therapy Against Adult T-Cell Leukemia
Authors: Tanaka Hiroki , Fujiwara Hiroshi , Ochi Fumihiro , Tanimoto Kazushi , Casey Nicholas , Okamoto Sachiko , Mineno Junichi , Kuzushima Kiyotaka , Shiku Hiroshi , Sugiyama Takashi , Barrett A. John , Yasukawa Masaki
Published: April 2023

ADCC activity mediated by cCD16Î¶-T cells against Mog-opsonized ATL tumor cells was dependent on both effector cell number and Mog dose. However, at a pharmacological dose of Mog, the decline of ADCC was more obviously dependent on the number of effector cells. (a) At a pharmacological dose of Mog (1Î¼g/mL), ADCC activity mediated by cCD16Î¶-T cells against Mog-opsonized ATL tumor cells declined sharply when the number of effector cells was lower. In order to exclude NK cell activity, K562-A24 was employed in this experiment as a negative control. Each experiment at the indicated dose of Mog was conducted in triplicate using three independent sets of cells from three different healthy donors. LCL, EBV-immortalized B cell line; Mog, mogamulizumab. Each experiment was conducted in triplicate (n=3). Error bars depict SD. (b) In the presence of a sufficient number of effector cells (E/T ratio 5:1), ADCC activity mediated by cCD16Î¶-T cells against ATL tumor cells was also Mog dose-dependent. However, at pharmacological doses of Mog (>0.1Î¼g/mL), the decline of ADCC activity was limited in comparison to that observed in S2a. LCL, EBV-immortalized B cell line: Mog, mogamulizumab. Each experiment was conducted in triplicate (n=3). Error bars depict SD.
Supplementary Figures 1-7. from SMARCA4/BRG1 Is a Novel Prognostic Biomarker Predictive of Cisplatin-Based Chemotherapy Outcomes in Resected Non–Small Cell Lung Cancer
Authors: Bell Erica Hlavin , Chakraborty Arup R. , Mo Xiaokui , Liu Ziyan , Shilo Konstantin , Kirste Simon , Stegmaier Petra , McNulty Maureen , Karachaliou Niki , Rosell Rafael , Bepler Gerold , Carbone David P. , Chakravarti Arnab
Published: April 2023

Supplementary Figure 1. SMARCA4 (212520_s_at) expression correlates with overall survival independent of stage in the Director's Challenge Study. Supplementary Figure 2. Low SMARCA4 (214360_at) expression correlates with decreased overall survival in the Director's Challenge Study. Supplementary Figure 3. Low SMARCA4 (208794_s_at) expression correlates with improved disease-specific survival with adjuvant cisplatin-based chemotherapy in the JBR.10 trial. Supplementary Figure 4. Low SMARCA4 (208794_s_at) expression correlates with improved overall survival with adjuvant cisplatin-based chemotherapy in the JBR.10 trial. Supplementary Figure 5. Low SMARCA4 (208793_x_at (A), 212520_s_at (B), 214360_at (C), and 215714_s_at (D)) expression correlates with improved disease-specific survival with adjuvant cisplatin-based chemotherapy in the JBR.10 trial. Supplementary Figure 6. SMARCA2 (206543_at) expression trends toward improved disease-specific survival with adjuvant cisplatin-based chemotherapy in the JBR.10 trial. Supplementary Figure 7. Mapping of the probe sets to the SMARCA4 gene.
Supplemental Figure 5 from Hepatitis B Virus X Protein (HBx) Is Responsible for Resistance to Targeted Therapies in Hepatocellular Carcinoma: Ex Vivo Culture Evidence
Authors: Huang Pinbo , Zhuang Baoxiong , Zhang Heyun , Yan Haiyan , Xiao Zhiyu , Li Wenbin , Zhang Jianlong , Tang Qibin , Hu Kaishun , Koeffler H. Phillip , Wang Jie , Yin Dong
Published: April 2023

Supplemental Figure 5. Effect of bortezomib and PD98059 in HBV+ and HBV- samples.
Supplementary Methods from miR-195 Inhibits Tumor Progression by Targeting RPS6KB1 in Human Prostate Cancer
Authors: Cai Chao , Chen Qing-Biao , Han Zhao-Dong , Zhang Yan-Qiong , He Hui-Chan , Chen Jia-Hong , Chen Yan-Ru , Yang Sheng-Bang , Wu Yong-Ding , Zeng Yan-Ru , Qin Guo-Qiang , Liang Yu-Xiang , Dai Qi-Shan , Jiang Fu-Neng , Wu Shu-lin , Zeng Guo-Hua , Zhong Wei-De , Wu Chin-Lee
Published: April 2023

Supplementary Methods
Supplementary figure legend from Correlating Surrogate Endpoints with Overall Survival at the Individual Patient Level in BRAFV600E-Mutated Metastatic Melanoma Patients Treated with Vemurafenib
Authors: Zabor Emily C. , Heller Glenn , Schwartz Lawrence H. , Chapman Paul B.
Published: April 2023

Figure legend for supplementary figure
Supplementary Table 1 from CD126 and Targeted Therapy with Tocilizumab in Chronic Lymphocytic Leukemia
Authors: Liu Feng-Ting , Jia Li , Wang Ping , Farren Timothy , Li Hong , Hao Xishan , Agrawal Samir G.
Published: April 2023

CD126 and Targeted Therapy with Tocilizumab in Chronic Lymphocytic Leukemia. Study population of CLL clinical and laboratory characteristics.
Supplementary Table 3 from Baseline Peripheral Blood Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with Ipilimumab
Authors: Martens Alexander , Wistuba-Hamprecht Kilian , Foppen Marnix Geukes , Yuan Jianda , Postow Michael A. , Wong Phillip , Romano Emanuela , Khammari Amir , Dreno Brigitte , Capone Mariaelena , Ascierto Paolo A. , Di Giacomo Anna Maria , Maio Michele , Schilling Bastian , Sucker Antje , Schadendorf Dirk , Hassel Jessica C. , Eigentler Thomas K. , Martus Peter , Wolchok Jedd D. , Blank Christian , Pawelec Graham , Garbe Claus , Weide Benjamin
Published: April 2023

Multivariate Models including only patients receiving 3 mg/kg ipilimumab. Lactate dehydrogenase (LDH), regulatory T cells (Tregs), myeloid-derived suppressor cells (MDSCs), hazard ratio (HR). * Relative lymphocyte count, absolute monocyte count, absolute and relative eosinophil count
Supplementary Table 2 from Baseline Peripheral Blood Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with Ipilimumab
Authors: Martens Alexander , Wistuba-Hamprecht Kilian , Foppen Marnix Geukes , Yuan Jianda , Postow Michael A. , Wong Phillip , Romano Emanuela , Khammari Amir , Dreno Brigitte , Capone Mariaelena , Ascierto Paolo A. , Di Giacomo Anna Maria , Maio Michele , Schilling Bastian , Sucker Antje , Schadendorf Dirk , Hassel Jessica C. , Eigentler Thomas K. , Martus Peter , Wolchok Jedd D. , Blank Christian , Pawelec Graham , Garbe Claus , Weide Benjamin
Published: April 2023

Spectrum of factors, cut-offs, and differences in overall survival according to biomarkers in the identification and the confirmation cohort. Absolute (Abs.), Relative (Rel.), Lactate dehydrogenase (LDH), regulatory T cells (Tregs), myeloid-derived suppressor cells (MDSCs). * Green characters indicate the category associated with better survival in the identification cohort. ** Green cells indicate significant differences in overall survival (p < 0.05). Red cells indicate non-significant findings.
Supplementary Table 1 from Baseline Peripheral Blood Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with Ipilimumab
Authors: Martens Alexander , Wistuba-Hamprecht Kilian , Foppen Marnix Geukes , Yuan Jianda , Postow Michael A. , Wong Phillip , Romano Emanuela , Khammari Amir , Dreno Brigitte , Capone Mariaelena , Ascierto Paolo A. , Di Giacomo Anna Maria , Maio Michele , Schilling Bastian , Sucker Antje , Schadendorf Dirk , Hassel Jessica C. , Eigentler Thomas K. , Martus Peter , Wolchok Jedd D. , Blank Christian , Pawelec Graham , Garbe Claus , Weide Benjamin
Published: April 2023

Panels of antibodies used for flow cytometry. * Cells were fixed and permeabilized with FoxP3 buffer (BD). Only frequencies of CD14+ cells from MDSC panel 1 and frequencies of CD4+, CD8+ T cells, as well as their ratio, were included from Treg panel 1. 1 Panel 1 (n=25), 2 Panel 2 (n=184).
Supplementary figure 5 from Genetic Engineering of T Cells to Target HERV-K, an Ancient Retrovirus on Melanoma
Authors: Krishnamurthy Janani , Rabinovich Brian A. , Mi Tiejuan , Switzer Kirsten C. , Olivares Simon , Maiti Sourindra N. , Plummer Joshua B. , Singh Harjeet , Kumaresan Pappanaicken R. , Huls Helen M. , Wang-Johanning Feng , Cooper Laurence J.N.
Published: April 2023

Supplementary figure 5. Generation and specificity of HERV-K env-specific CAR+ ffLuc+ T cells in vitro and in vivo.
Supplementary Figure Legends from Targeting the Spleen Tyrosine Kinase with Fostamatinib as a Strategy against Waldenström Macroglobulinemia
Authors: Kuiatse Isere , Baladandayuthapani Veerabhadran , Lin Heather Y. , Thomas Sheeba K. , Bjorklund Chad C. , Weber Donna M. , Wang Michael , Shah Jatin J. , Zhang Xing-Ding , Jones Richard J. , Ansell Stephen M. , Yang Guang , Treon Steven P. , Orlowski Robert Z.
Published: April 2023

Supplementary Figure Legends
Supplementary figure 1 and 2 from Genetic Engineering of T Cells to Target HERV-K, an Ancient Retrovirus on Melanoma
Authors: Krishnamurthy Janani , Rabinovich Brian A. , Mi Tiejuan , Switzer Kirsten C. , Olivares Simon , Maiti Sourindra N. , Plummer Joshua B. , Singh Harjeet , Kumaresan Pappanaicken R. , Huls Helen M. , Wang-Johanning Feng , Cooper Laurence J.N.
Published: April 2023

Supplementary figure 1 and 2. Figure S1: HERV-K env expression on primary tumor and normal human tissues. Figure. S2: Phenotype and mRNA profile of HERV-K env-specific CAR+ T cells.
Supplementary Video D from Genetic Engineering of T Cells to Target HERV-K, an Ancient Retrovirus on Melanoma
Authors: Krishnamurthy Janani , Rabinovich Brian A. , Mi Tiejuan , Switzer Kirsten C. , Olivares Simon , Maiti Sourindra N. , Plummer Joshua B. , Singh Harjeet , Kumaresan Pappanaicken R. , Huls Helen M. , Wang-Johanning Feng , Cooper Laurence J.N.
Published: April 2023

Supplementary Video D. Physical health of mice group with tumor and without HERV-K env-specific CAR+ T-cell treatment.
Supplementary Legend from Incorporation of Next-Generation Sequencing into Routine Clinical Care to Direct Treatment of Head and Neck Squamous Cell Carcinoma
Authors: Chau Nicole G. , Li Yvonne Y. , Jo Vickie Y. , Rabinowits Guilherme , Lorch Jochen H. , Tishler Roy B. , Margalit Danielle N. , Schoenfeld Jonathan D. , Annino Don J. , Goguen Laura A. , Thomas Tom , Becker Hailey , Haddad Tyler , Krane Jeffrey F. , Lindeman Neal I. , Shapiro Geoffrey I. , Haddad Robert I. , Hammerman Peter S.
Published: April 2023

Supplementary Figure Legend
Supplementary Figure 6 and 7 from Incorporation of Next-Generation Sequencing into Routine Clinical Care to Direct Treatment of Head and Neck Squamous Cell Carcinoma
Authors: Chau Nicole G. , Li Yvonne Y. , Jo Vickie Y. , Rabinowits Guilherme , Lorch Jochen H. , Tishler Roy B. , Margalit Danielle N. , Schoenfeld Jonathan D. , Annino Don J. , Goguen Laura A. , Thomas Tom , Becker Hailey , Haddad Tyler , Krane Jeffrey F. , Lindeman Neal I. , Shapiro Geoffrey I. , Haddad Robert I. , Hammerman Peter S.
Published: April 2023

Supplementary Figure 6: Presence of GATA4 Amplification is Associated with Overall Survival Across the Oncopanel Cohort (n=109). Supplementary Figure 7: Presence of PIK3CA Tier1/2 Mutations Alone, without Considering Copy Number Amplifications, is not Associated with Progression-Free Survival Across the HNSCC Cohort (n=213).
Figure S4 from Development and Validation of a Six-Gene Recurrence Risk Score Assay for Gastric Cancer
Authors: Lee Keun-Wook , Lee Sung Sook , Hwang Jun-Eul , Jang Hee-Jin , Lee Hyun-Sung , Oh Sang Cheul , Lee Sang Ho , Sohn Bo Hwa , Kim Sang Bae , Shim Jae-Jun , Jeong Woojin , Cha Minse , Cheong Jae-Ho , Cho Jae Yong , Lim Jae Yun , Park Eun Sung , Kim Sang Cheol , Kang Yoon-Koo , Noh Sung Hoon , Ajani Jaffer A. , Lee Ju-Seog
Published: April 2023

Hierarchical clustering analysis of YAP1 signature in 5 GC cell lines.
Supplementary Figure legends from A Pilot Trial Using Lymphocytes Genetically Engineered with an NY-ESO-1–Reactive T-cell Receptor: Long-term Follow-up and Correlates with Response
Authors: Robbins Paul F. , Kassim Sadik H. , Tran Thai L.N. , Crystal Jessica S. , Morgan Richard A. , Feldman Steven A. , Yang James C. , Dudley Mark E. , Wunderlich John R. , Sherry Richard M. , Kammula Udai S. , Hughes Marybeth S. , Restifo Nicholas P. , Raffeld Mark , Lee Chyi-Chia R. , Li Yong F. , El-Gamil Mona , Rosenberg Steven A.
Published: April 2023

Legends for Supplementary Figures 1 and 2
Supplemental Figure 4 from Activity of MM-398, Nanoliposomal Irinotecan (nal-IRI), in Ewing's Family Tumor Xenografts Is Associated with High Exposure of Tumor to Drug and High SLFN11 Expression
Authors: Kang Min H. , Wang Jing , Makena Monish R. , Lee Joo-Sang , Paz Nancy , Hall Connor P. , Song Michael M. , Calderon Ruben I. , Cruz Riza E. , Hindle Ashly , Ko Winford , Fitzgerald Jonathan B. , Drummond Daryl C. , Triche Timothy J. , Reynolds C. Patrick
Published: April 2023

Supplementary Figure 4: Inverse correlation between sensitivity to DNA damaging agents and SLFN11 expression.
Supplemental Figure 1 from Activity of MM-398, Nanoliposomal Irinotecan (nal-IRI), in Ewing's Family Tumor Xenografts Is Associated with High Exposure of Tumor to Drug and High SLFN11 Expression
Authors: Kang Min H. , Wang Jing , Makena Monish R. , Lee Joo-Sang , Paz Nancy , Hall Connor P. , Song Michael M. , Calderon Ruben I. , Cruz Riza E. , Hindle Ashly , Ko Winford , Fitzgerald Jonathan B. , Drummond Daryl C. , Triche Timothy J. , Reynolds C. Patrick
Published: April 2023

Supplementary Figure 1: Changes in body weight of mice treated with vehicle.
Supplemental Fig. 1 from Notch Pathway Inhibition Using PF-03084014, a γ-Secretase Inhibitor (GSI), Enhances the Antitumor Effect of Docetaxel in Prostate Cancer
Authors: Cui Di , Dai Jinlu , Keller Jill M. , Mizokami Atsushi , Xia Shujie , Keller Evan T.
Published: April 2023

Supplemental Figure 1. Genetic knockdown of Notch-1 inhibits growth and docetaxel chemoresistance of prostate cancer cells similar to PF-03084014.
Supplementary Table 1 from Significance of Circulating Tumor Cells in Metastatic Triple-Negative Breast Cancer Patients within a Randomized, Phase II Trial: TBCRC 019
Authors: Paoletti Costanza , Li Yufeng , Muñiz Maria C. , Kidwell Kelley M. , Aung Kimberly , Thomas Dafydd G. , Brown Martha E. , Abramson Vandana G. , Irvin William J. , Lin Nancy U. , Liu Minetta C. , Nanda Rita , Nangia Julie R. , Storniolo Anna M. , Traina Tiffany A. , Vaklavas Christos , Van Poznak Catherine H. , Wolff Antonio C. , Forero-Torres Andres , Hayes Daniel F.
Published: April 2023

Supplementary Table 1. Table illustrating the criteria with which a cell was considered viable, or apoptotic either due to positive M-30 staining and/or visual evidence of apoptosis (nucleic condensat). Legend: Y= Yes, N= No
Supplementary Figure 1-5 from Significance of Circulating Tumor Cells in Metastatic Triple-Negative Breast Cancer Patients within a Randomized, Phase II Trial: TBCRC 019
Authors: Paoletti Costanza , Li Yufeng , Muñiz Maria C. , Kidwell Kelley M. , Aung Kimberly , Thomas Dafydd G. , Brown Martha E. , Abramson Vandana G. , Irvin William J. , Lin Nancy U. , Liu Minetta C. , Nanda Rita , Nangia Julie R. , Storniolo Anna M. , Traina Tiffany A. , Vaklavas Christos , Van Poznak Catherine H. , Wolff Antonio C. , Forero-Torres Andres , Hayes Daniel F.
Published: April 2023

Supplementary Figure 1-5. Supplementary Figure 1. Example of cluster image using the CellSearch® system. Supplementary Figure 2. REMARK diagram of the 19 patients who had elevated CTC (Group B/C) at baseline that were used to study "CTC-response". Supplementary Figure 3. PFS for TIG-treated patients versus the control group according to baseline CTC levels: CTC <5 (S2A) vs. {greater than or equal to}5 /7.5 ml WB (S2B) (note difference in time scale on y-axis). Supplementary Figure 4. Association of CTC-response level with RECIST response: ORR and CBR for group B and C as stated above. (Clinical response= either overall response rate (ORR) or clinical benefit response (CBR), as defined in method). Supplementary Figure 5. Association of CTC-apoptosis and response with RECIST response ORR and CBR. (Clinical response= either overall response rate (ORR) or clinical benefit response (CBR), as defined in method).
Supplementary Figure 6 from A Vaccinia Virus Armed with Interleukin-10 Is a Promising Therapeutic Agent for Treatment of Murine Pancreatic Cancer
Authors: Chard Louisa S. , Maniati Eleni , Wang Pengju , Zhang Zhongxian , Gao Dongling , Wang Jiwei , Cao Fengyu , Ahmed Jahangir , El Khouri Margueritte , Hughes Jonathan , Wang Shengdian , Li Xiaozhu , Denes Bela , Fodor Istvan , Hagemann Thorsten , Lemoine Nicholas R. , Wang Yaohe
Published: April 2023

Supplementary Figure 6. Example FACS profiles of CD4+, CD8+, activated and naive T cells.
Supplementary Figure 3 from A Vaccinia Virus Armed with Interleukin-10 Is a Promising Therapeutic Agent for Treatment of Murine Pancreatic Cancer
Authors: Chard Louisa S. , Maniati Eleni , Wang Pengju , Zhang Zhongxian , Gao Dongling , Wang Jiwei , Cao Fengyu , Ahmed Jahangir , El Khouri Margueritte , Hughes Jonathan , Wang Shengdian , Li Xiaozhu , Denes Bela , Fodor Istvan , Hagemann Thorsten , Lemoine Nicholas R. , Wang Yaohe
Published: April 2023

Supplementary Figure 3. Macrophage infiltration into pancreatic tumors of KPC mice
Supplementary Figure S3 from A Serum MicroRNA Signature Predicts Tumor Relapse and Survival in Triple-Negative Breast Cancer Patients
Authors: Kleivi Sahlberg Kristine , Bottai Giulia , Naume Bjørn , Burwinkel Barbara , Calin George A. , Børresen-Dale Anne-Lise , Santarpia Libero
Published: April 2023

Supplementary Figure S3. MicroRNA levels in healthy and malignant breast tissue
Supplementary Figures from RING-Finger Protein 6 Amplification Activates JAK/STAT3 Pathway by Modifying SHP-1 Ubiquitylation and Associates with Poor Outcome in Colorectal Cancer
Authors: Liang Qian , Ma Dan , Zhu Xiaoqiang , Wang Zhenhua , Sun Tian-Tian , Shen Chaoqin , Yan Tingting , Tian Xianglong , Yu TaChung , Guo Fangfang , Tang JiaYin , Lin Yanwei , Chen Huimin , Zhou Chao , Ge Zhizheng , Zhong Ming , Chen Jinxian , Liu Qiang , Wang Zheng , Fang Jing-Yuan , Chen Haoyan , Hong Jie
Published: April 2023

Fig. S1. RNF6 genomic amplification is prevalent in colorectal cancer and correlated with shortened patient survival. Fig. S2. RNF6 is clinically relevant in colorectal cancer. Fig. S3. Gene Ontology (GO) and Gene Set Enrichment Analysis (GSEA) in RNF6-higher/lower expression CRC cells and patients, and RNF6 is an oncogenic gene. FigureS4. RNF6 upregulates pSTAT3 via downregulating SHP-1 expression. Figure S5. RNF6 Interacts with SHP-1 and enhances ubiquitylation and degradation of SHP-1. Figure S6. Effectiveness of pSTAT3 inhibitors in treating RNF6-amplified tumors.
Supplementary Figure legends from RING-Finger Protein 6 Amplification Activates JAK/STAT3 Pathway by Modifying SHP-1 Ubiquitylation and Associates with Poor Outcome in Colorectal Cancer
Authors: Liang Qian , Ma Dan , Zhu Xiaoqiang , Wang Zhenhua , Sun Tian-Tian , Shen Chaoqin , Yan Tingting , Tian Xianglong , Yu TaChung , Guo Fangfang , Tang JiaYin , Lin Yanwei , Chen Huimin , Zhou Chao , Ge Zhizheng , Zhong Ming , Chen Jinxian , Liu Qiang , Wang Zheng , Fang Jing-Yuan , Chen Haoyan , Hong Jie
Published: April 2023

Fig. S1. RNF6 genomic amplification is prevalent in colorectal cancer and correlated with shortened patient survival. Fig. S2. RNF6 is clinically relevant in colorectal cancer. Fig. S3. Gene Ontology (GO) and Gene Set Enrichment Analysis (GSEA) in RNF6-higher/lower expression CRC cells and patients, and RNF6 is an oncogenic gene. FigureS4. RNF6 upregulates pSTAT3 via downregulating SHP-1 expression. Figure S5. RNF6 Interacts with SHP-1 and enhances ubiquitylation and degradation of SHP-1. Figure S6. Effectiveness of pSTAT3 inhibitors in treating RNF6-amplified tumors.
Supplementary Materials from MAPK Activation Predicts Poor Outcome and the MEK Inhibitor, Selumetinib, Reverses Antiestrogen Resistance in ER-Positive High-Grade Serous Ovarian Cancer
Authors: Hew Karina E. , Miller Philip C. , El-Ashry Dorraya , Sun Jun , Besser Alexandra H. , Ince Tan A. , Gu Mengnan , Wei Zhi , Zhang Gao , Brafford Patricia , Gao Wei , Lu Yiling , Mills Gordon B. , Slingerland Joyce M. , Simpkins Fiona
Published: April 2023

Supplementary Materials
Supplemental Table 1 from SMO Gene Amplification and Activation of the Hedgehog Pathway as Novel Mechanisms of Resistance to Anti-Epidermal Growth Factor Receptor Drugs in Human Lung Cancer
Authors: Della Corte Carminia Maria , Bellevicine Claudio , Vicidomini Giovanni , Vitagliano Donata , Malapelle Umberto , Accardo Marina , Fabozzi Alessio , Fiorelli Alfonso , Fasano Morena , Papaccio Federica , Martinelli Erika , Troiani Teresa , Troncone Giancarlo , Santini Mario , Bianco Roberto , Ciardiello Fortunato , Morgillo Floriana
Published: April 2023

EGFR mutational status, gefitinib sensitivity and HH pathway activation in our panel of NSCLC cell lines.
Figure S3 from PKCα Attenuates Jagged-1–Mediated Notch Signaling in ErbB-2–Positive Breast Cancer to Reverse Trastuzumab Resistance
Authors: Pandya Kinnari , Wyatt Debra , Gallagher Brian , Shah Deep , Baker Andrew , Bloodworth Jeffrey , Zlobin Andrei , Pannuti Antonio , Green Andrew , Ellis Ian O. , Filipovic Aleksandra , Sagert Jason , Rana Ajay , Albain Kathy S. , Miele Lucio , Denning Mitchell F. , Osipo Clodia
Published: April 2023

A. Expression of phosphorylated ErbB2, AKT1, and ERK1/1 proteins in response to lapatinib, LY294002, or U0126. B. Expression of PKCα and phosphorylated Serine in substrates by Western blotting in trastuzumab resistant and sensitive BT474 cells.
Supplemental Table 3 from Bias-Corrected Targeted Next-Generation Sequencing for Rapid, Multiplexed Detection of Actionable Alterations in Cell-Free DNA from Advanced Lung Cancer Patients
Authors: Paweletz Cloud P. , Sacher Adrian G. , Raymond Chris K. , Alden Ryan S. , O'Connell Allison , Mach Stacy L. , Kuang Yanan , Gandhi Leena , Kirschmeier Paul , English Jessie M. , Lim Lee P. , Jänne Pasi A. , Oxnard Geoffrey R.
Published: April 2023

Supplemental Table 3: Summary of ddPCR and NGS findings. The table shows the tissue genotype, ddPCR results, ddPCR allele frequency (mut / mut +wt allele frequency), NGS mutation calls and allele frequencies, and sequencing reads.
Supplemental Table 2 from Bias-Corrected Targeted Next-Generation Sequencing for Rapid, Multiplexed Detection of Actionable Alterations in Cell-Free DNA from Advanced Lung Cancer Patients
Authors: Paweletz Cloud P. , Sacher Adrian G. , Raymond Chris K. , Alden Ryan S. , O'Connell Allison , Mach Stacy L. , Kuang Yanan , Gandhi Leena , Kirschmeier Paul , English Jessie M. , Lim Lee P. , Jänne Pasi A. , Oxnard Geoffrey R.
Published: April 2023

Supplemental Table 2: Compilation of cell line admixture experimental data. The table shows the number of detected mutant reads, the total number of wild-type reads that correspond to the genomic coordinates of the mutant allele, and the frequency of mutant allele detection.
Supplemental Table 1 from Bias-Corrected Targeted Next-Generation Sequencing for Rapid, Multiplexed Detection of Actionable Alterations in Cell-Free DNA from Advanced Lung Cancer Patients
Authors: Paweletz Cloud P. , Sacher Adrian G. , Raymond Chris K. , Alden Ryan S. , O'Connell Allison , Mach Stacy L. , Kuang Yanan , Gandhi Leena , Kirschmeier Paul , English Jessie M. , Lim Lee P. , Jänne Pasi A. , Oxnard Geoffrey R.
Published: April 2023

Supplemental Table 1: Summary of probe sequences
Supplemental Methods from Bias-Corrected Targeted Next-Generation Sequencing for Rapid, Multiplexed Detection of Actionable Alterations in Cell-Free DNA from Advanced Lung Cancer Patients
Authors: Paweletz Cloud P. , Sacher Adrian G. , Raymond Chris K. , Alden Ryan S. , O'Connell Allison , Mach Stacy L. , Kuang Yanan , Gandhi Leena , Kirschmeier Paul , English Jessie M. , Lim Lee P. , Jänne Pasi A. , Oxnard Geoffrey R.
Published: April 2023

File contains Supplemental Methods section and captions/descriptions for Supplemental Table 1, Supplemental Table 2, Supplemental Table 3, Supplemental Figure 1, Supplemental Figure 2 and Supplemental Figure 3.
Supplemental Figure 1 from Generation 2.5 Antisense Oligonucleotides Targeting the Androgen Receptor and Its Splice Variants Suppress Enzalutamide-Resistant Prostate Cancer Cell Growth
Authors: Yamamoto Yoshiaki , Loriot Yohann , Beraldi Eliana , Zhang Fan , Wyatt Alexander W. , Nakouzi Nader Al , Mo Fan , Zhou Tianyuan , Kim Youngsoo , Monia Brett P. , MacLeod A. Robert , Fazli Ladan , Wang Yuzhuo , Collins Colin C. , Zoubeidi Amina , Gleave Martin
Published: April 2023

Supplemental Figure 1. AR full length and AR-V7 mRNA expression is up-regulated by ENZ treatment in LNCaP cells.
Supplementary Figure S6 from Radiation Enhancement of Head and Neck Squamous Cell Carcinoma by the Dual PI3K/mTOR Inhibitor PF-05212384
Authors: Leiker Andrew J. , DeGraff William , Choudhuri Rajani , Sowers Anastasia L. , Thetford Angela , Cook John A. , Van Waes Carter , Mitchell James B.
Published: April 2023

Supplementary Figure S6. Heat map of individual mRNA absolute Ct obtained from senescence pathway directed RT-PCR of UMSCC1 cells treated with 24 hour PF-05212384 (10 Î¼M) or DMSO (10 Î¼M) followed by irradiation (10 Gy) or mock irradiation.
Supplementary Table 1 from Sustained Inhibition of HER3 and EGFR Is Necessary to Induce Regression of HER2-Amplified Gastrointestinal Carcinomas
Authors: Leto Simonetta M. , Sassi Francesco , Catalano Irene , Torri Valter , Migliardi Giorgia , Zanella Eugenia R. , Throsby Mark , Bertotti Andrea , Trusolino Livio
Published: April 2023

Quantitations of phosphoproteins in cell lines and tumorgrafts treated with HER2/EGFR small-molecule inhibitors and antibodies.
Supplementary Figure S4 from Radiation Enhancement of Head and Neck Squamous Cell Carcinoma by the Dual PI3K/mTOR Inhibitor PF-05212384
Authors: Leiker Andrew J. , DeGraff William , Choudhuri Rajani , Sowers Anastasia L. , Thetford Angela , Cook John A. , Van Waes Carter , Mitchell James B.
Published: April 2023

Supplementary Figure S4. The effects of PF-05212384 (10μM) on UMSCC46 radiation induced DNA damage repair.
Supplementary Figure S2 from Sustained Inhibition of HER3 and EGFR Is Necessary to Induce Regression of HER2-Amplified Gastrointestinal Carcinomas
Authors: Leto Simonetta M. , Sassi Francesco , Catalano Irene , Torri Valter , Migliardi Giorgia , Zanella Eugenia R. , Throsby Mark , Bertotti Andrea , Trusolino Livio
Published: April 2023

Generation and biological characterization of HER2-overexpressing DiFi and HDC-142 cells.
Supplementary Methods and Legends from Cotargeting of Epidermal Growth Factor Receptor and PI3K Overcomes PI3K–Akt Oncogenic Dependence in Pancreatic Ductal Adenocarcinoma
Authors: Wong Matthew H. , Xue Aiqun , Julovi Sohel M. , Pavlakis Nick , Samra Jaswinder S. , Hugh Thomas J. , Gill Anthony J. , Peters Lyndsay , Baxter Robert C. , Smith Ross C.
Published: April 2023

Supplementary Methods and Legends
Supplementary Figure Legends from Myeloid Cells and Related Chronic Inflammatory Factors as Novel Predictive Markers in Melanoma Treatment with Ipilimumab
Authors: Gebhardt Christoffer , Sevko Alexandra , Jiang Huanhuan , Lichtenberger Ramtin , Reith Maike , Tarnanidis Kathrin , Holland-Letz Tim , Umansky Ludmila , Beckhove Philipp , Sucker Antje , Schadendorf Dirk , Utikal Jochen , Umansky Viktor
Published: April 2023

Frequencies and NO production by moMDSCs (Supplementary Fig.1) and serum eotaxin-1 levels in non-responders and responders (Supplementary Fig.2)
Supplementary Figure S5 from Cotargeting of Epidermal Growth Factor Receptor and PI3K Overcomes PI3K–Akt Oncogenic Dependence in Pancreatic Ductal Adenocarcinoma
Authors: Wong Matthew H. , Xue Aiqun , Julovi Sohel M. , Pavlakis Nick , Samra Jaswinder S. , Hugh Thomas J. , Gill Anthony J. , Peters Lyndsay , Baxter Robert C. , Smith Ross C.
Published: April 2023

Figure S5: Effect of single and dual blockade (DB) on cell proliferation (A, B) 3D contour maps for inhibition by ERL+AEW (A) and ERL+BYL (B). Synergy index (SI) was calculated by non-linear regression (PROC NLIN) using the Bliss synergy/antagonism formula. SI>1 indicates synergy and SI<1 indicates antagonism between two drugs. If the 95% confidence interval does not cross 1, the effect is significant. (C) Proliferation of control and ER cell lines was measured in real-time over 70 h of drug treatment. Treatments are control (black solid), erlotinib 10 ÂµM (E10- black dotted), NVP-AEW541 1 ÂµM (A1- black dashed), NVP-BYL719 5 ÂµM (B5- grey solid), E10A1 (E10+ A1- grey dotted), and E10B5 (E10+ B5- grey dashed). Mean values {plus minus} SEM for 4 experiments.
Supplementary Figure S3 from Cotargeting of Epidermal Growth Factor Receptor and PI3K Overcomes PI3K–Akt Oncogenic Dependence in Pancreatic Ductal Adenocarcinoma
Authors: Wong Matthew H. , Xue Aiqun , Julovi Sohel M. , Pavlakis Nick , Samra Jaswinder S. , Hugh Thomas J. , Gill Anthony J. , Peters Lyndsay , Baxter Robert C. , Smith Ross C.
Published: April 2023

Figure S3: Phospho-RTK array on ER versus parental cell lines (A) Phosphorylated protein chemiluminescence intensity in untreated (NT) parental and resistant cells after adjusting to positive and negative controls, with the largest differences in signal intensity shaded in grey (B) Quantitation of Western blotting results of pERK, pAkt and pS6 adjusted to total proteins in ER and parental cell lines, either untreated (NT) or after stimulation by EGF, IGF-1, or both growth factors. * P<0.05
Supplementary Table 2 from Epigenetics Markers of Metastasis and HPV-Induced Tumorigenesis in Penile Cancer
Authors: Feber Andrew , Arya Manit , de Winter Patricia , Saqib Muhammad , Nigam Raj , Malone Peter R. , Tan Wei Shen , Rodney Simon , Lechner Matthias , Freeman Alex , Jameson Charles , Muneer Asif , Beck Stephan , Kelly John D.
Published: April 2023

Supplementary Table 2. Primers sequences for A) HPV primers, B)analysis of CDO1 and AR gene expression and C) MSP analysis of HMX3, PPP2R5C, IRF4, FLI1.